| INTRODUCTION – Leonard G. Gomella, Daniel P. Petrylak, Bobby Shayegan | 13 |
| The changing landscape of advanced and castration resistant prostate cancer: latest science and revised definitions – Derya Tilki, Christopher P. Evans | 19 |
| Traditional androgen ablation approaches to advanced prostate cancer: new insights – Kyle O. Rove, E. David Crawford | 26 |
| Utility of LHRH antagonists for advanced prostate cancer cancer – Judd W. Moul | 34 |
| Secondary hormonal manipulation in castration resistant prostate cancer – Sohaib Al-Asaaed, Eric Winquist | 49 |
| Imaging approaches with advanced prostate cancer: techniques and timing – David Leung, Saravanan Krishnamoorthy, Lawrence Schwartz, Chaitanya Divgi | 54 |
| Practical guide to immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T immunotherapy – Leonard G. Gomella, Francisco Gelpi-Hammerschmidt, Chandan Kundavram | 60 |
| Practical guide to the use of abiraterone in castration resistant prostate cancer – Elahe A. Mostaghel, Daniel W. Lin | 69 |
| Practical guide to the use of enzalutamide – Jean Hoffman-Censits, Wm. Kevin Kelly | 76 |
| Practical guide to the use of radium 223 dichloride – Robert B. Den, Laura A. Doyle, Karen E. Knudsen | 82 |
| Practical guide to the use of chemotherapy in castration resistant prostate cancer – Daniel P. Petrylak | 89 |
| Practical guide to bone health in the spectrum of advanced prostate cancer – Valentina Butoescu, Bertrand Tombal | 96 |
| How to approach sequencing therapy in patients with metastatic castration resistant prostate cancer – Robert Dreicer | 105 |
| Emerging therapies in castration resistant prostate cancer – Gregory R. Thoreson, Bishoy A. Gayed, Paul H. Chung, Ganesh V. Raj | 110 |
| Post-Test for CME | 118 |